caa a22 4500 378869655 CHVBK 20180305123406.0 cr unu---uuuuu 161128e20030127xx s 000 0 eng 10.1515/CCLM.2003.016 doi (NATIONALLICENCE)gruyter-10.1515/CCLM.2003.016 A New Modification of the Chiron ACSAssay for Total Prostate-Specific Antigen AchievesEquimolar Response Characteristics andImproves the Detection of ProstateCancer [Elektronische Daten] [Frank Oberpenning, Christoph Weining, Burkhard Brandt, Gabriela De Angelis, Achim Heinecke, Michael Hamm, Petra Stieber, Lothar Hertle, Hans-Peter Schmid, Axel Semjonow] Nonequimolar-response assays for prostate-specific antigen (PSA) are criticized for overestimating total PSA in some men without prostate cancer (PCA), and underestimating total PSA in some men with PCA. We recently studied three nonequimolar-response PSA assays that had undergone modifications. While two of the studied assays achieved equimolar-response characteristics with improved areas under receiver operating characteristic (ROC) curves (AUC), the modification of the Chiron ACS PSA assay (ACS PSA2, Chiron) failed to achieve this. Recently, the ACS assay underwent another modification (ACS PSA, Bayer), which we investigated. Sera from 305 men (155 without and 150 with PCA, PSA ≥2 and ≤30 μg/l, Tandem-E) were measured using both modifications of the ACS assay and equimolar-response reference methods (Tandem-R free and Tandem- E, Hybritech). Molar response relative to the reference method and clinical performance (comparison of AUCs) between the previous and new ACS assay modifications were studied. The new modification of the ACS assay (ACS PSA, Bayer) achieved equimolar-response characteristics but reported lower values (average 10%) than the Tandem-E assay. Compared to the previous modification (ACS PSA2, Chiron), a 3% improvement in AUC (p = 0.01) was found. Using results of the redesigned equimolar-response assay (ACS PSA, Bayer), we calculated that 6 of 155 men without PCA in this sample set could be spared unnecessary biopsy compared with the previous nonequimolar-response assay (ACS PSA2, Chiron) without missing additional PCA (90% sensitivity). These data provide additional evidence for clinical advantages of equimolar-response over nonequimolar-response PSA assay formats. Copyright © 2003 by Walter de Gruyter GmbH & Co. KG Medical equipment & techniques nationallicence Medical diagnosis nationallicence Diseases & disorders nationallicence Oberpenning Frank aut Weining Christoph aut Brandt Burkhard aut De Angelis Gabriela aut Heinecke Achim aut Hamm Michael aut Stieber Petra aut Hertle Lothar aut Schmid Hans-Peter aut Semjonow Axel aut Clinical Chemistry and Laboratory Medicine Walter de Gruyter 41/1(2003-01-27), 90-94 1434-6621 41:1<90 2003 41 cclm https://doi.org/10.1515/CCLM.2003.016 text/html Onlinezugriff via DOI 1 research article jats NATIONALLICENCE 856 40 https://doi.org/10.1515/CCLM.2003.016 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Oberpenning Frank aut NATIONALLICENCE 700 1- Weining Christoph aut NATIONALLICENCE 700 1- Brandt Burkhard aut NATIONALLICENCE 700 1- De Angelis Gabriela aut NATIONALLICENCE 700 1- Heinecke Achim aut NATIONALLICENCE 700 1- Hamm Michael aut NATIONALLICENCE 700 1- Stieber Petra aut NATIONALLICENCE 700 1- Hertle Lothar aut NATIONALLICENCE 700 1- Schmid Hans-Peter aut NATIONALLICENCE 700 1- Semjonow Axel aut NATIONALLICENCE 773 0- Clinical Chemistry and Laboratory Medicine Walter de Gruyter 41/1(2003-01-27), 90-94 1434-6621 41:1<90 2003 41 cclm CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-gruyter